Truqap (Capivasertib) Patent Expiration, LOE Window & CMS Spending
Truqap (Capivasertib) by AstraZeneca: FDA Orange Book core substance LOE 2033-04-16, 0 AB generics, $214.6M 2024 CMS Part D & Medicaid spend, and $22,922 CA SB 17 specialty launch WAC.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | AstraZeneca |
| FDA Application & Pathway | N218197 (NDA) |
| Exclusivity / Cliff Horizon | Mid-Term Protection (2031-2035) |
| Core Active-Ingredient LOE Date | 2033-04-16 |
| Last Listed Patent or Exclusivity Date | 2033-04-16 |
| Orange Book Patents (*PED Extensions) | 9 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $214.6M |
| 2024 Medicare Part D Spend | $184.2M |
| 2024 Medicaid Spend | $30.4M |
| Reported Wholesale Price Change (CA SB 17) | Specialty launch notice ($22,922 intro WAC) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for AstraZeneca across sibling Meru public-data platforms.